Yasutaka Ishii

Dr. Yasutaka Ishii

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
JIJuri Ikemoto
Juri Ikemoto
MSMasahiro Serikawa
Masahiro Serikawa
Keiji HanadaKeiji Hanada
Keiji Hanada
NENoriaki Eguchi
Noriaki Eguchi
TSTamito Sasaki
Tamito Sasaki
KCKazuaki Chayama
Kazuaki Chayama
Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) is challenging but essential for improving its poor prognosis. We established a multicenter study to clarify the clinicopathological features, and to propose new algorithm for early diagnosis of PDAC. Ninety-six patients with stage 0 and IA PDAC were enrolled from 13 high-volume centers. Overall, 70% of the patients were asymptomatic. The serum pancreatic enzyme levels were abnormal in half of the patients. The sensitivity of endoscopic ultrasonography (EUS) for detecting small PDAC was superior to computed tomography and magnetic resonance imaging (MRI) (82%, 58%, and 38%, respectively). Indirect imaging findings were useful to detect early-stage PDAC; especially, main pancreatic duct stenosis on MRI had the highest positive rate of 86% in stage 0 patients. For preoperative pathological diagnosis, the sensitivity of endoscopic retrograde cholangiopancreatography (ERCP)-associated pancreatic juice cytology was 84%. Among the stage IA patients, EUS-guided fine-needle aspiration revealed adenocarcinoma in 93% patients. For early diagnosis of PDAC, it is essential to identify asymptomatic patients and ensure close examinations of indirect imaging findings and standardization of preoperative pathological diagnosis. Therefore, a new diagnostic algorithm based on tumor size and imaging findings should be developed.

17 August 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
SNShinya Nakamura
Shinya Nakamura
YIYasutaka Ishii
Yasutaka Ishii
MSMasahiro Serikawa
Masahiro Serikawa
Keiji HanadaKeiji Hanada
Keiji Hanada
NENoriaki Eguchi
Noriaki Eguchi
SOShiro Oka
Shiro Oka
Pathological examination is essential for the diagnosis and treatment of pancreatic ductal adenocarcinoma (PDAC). Moreover, a reliable pathological diagnosis is extremely important for improving prognosis, especially in early-stage PDAC. This study prospectively evaluated the usefulness of repeated pancreatic juice cytology (PJC) using an endoscopic nasopancreatic drainage (ENPD) catheter for the diagnosis of PDAC. We enrolled 82 patients suspected of having resectable PDAC, based on imaging studies, and judged the necessity for cytology. The diagnostic yield of up to six repeated PJCs and the incidence of complications, such as pancreatitis, was evaluated. A total of 60 patients were diagnosed with PDAC. The overall sensitivity and specificity were 46.7% and 95.5%, respectively. The cumulative positivity rate increased with the number of sampling sessions, reaching 58.3% in the sixth session. The sensitivity was significantly higher in the pancreatic head than in the pancreatic tail (p = 0.043). Additionally, it was 100% in four patients with a tumor size ≤10 mm. Pancreatitis occurred in six patients (7.3%), all of whom were treated conservatively. In the diagnosis of PDAC, repeated PJC using an ENPD catheter revealed a cumulative effect of sensitivity up to six times and an excellent diagnostic yield for small PDAC.

8 February 2022 in Pancreatology
Verified
Journal Article
Closed access
RKRyota Kawamura
Ryota Kawamura
YIYasutaka Ishii
Yasutaka Ishii
MSMasahiro Serikawa
Masahiro Serikawa
TTTomofumi Tsuboi
Tomofumi Tsuboi
KTKen Tsushima
Ken Tsushima
HAHiroshi Aikata
Hiroshi Aikata

16 May 2021 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
SNShinya Nakamura
Shinya Nakamura
YIYasutaka Ishii
Yasutaka Ishii
MSMasahiro Serikawa
Masahiro Serikawa
TTTomofumi Tsuboi
Tomofumi Tsuboi
RKRyota Kawamura
Ryota Kawamura
KCKazuaki Chayama
Kazuaki Chayama

1 February 2019 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
YIYasutaka Ishii
Yasutaka Ishii
MSMasahiro Serikawa
Masahiro Serikawa
TSTamito Sasaki
Tamito Sasaki
YFYoshifumi Fujimoto
Yoshifumi Fujimoto
AYAtsushi Yamaguchi
Atsushi Yamaguchi
KCKazuaki Chayama
Kazuaki Chayama
Objectives: Steroids are the first-line drugs for induction of remission in patients with type 1 autoimmune pancreatitis (AIP), and the usefulness of steroid maintenance therapy to prevent relapse has recently been reported. However, even during steroid therapy, a relatively large percentage of patients relapse and the predictive factors for relapse have not yet been elucidated. The aim of this study was to clarify the predictive factors for relapse of AIP patients during steroid therapy. Materials and methods: The medical records of 76 patients with type 1 AIP with continued steroid therapy after induction of remission were analyzed retrospectively. The relapse rate during steroid therapy was evaluated, and the risk factors for relapse were investigated by univariate and multivariate analysis of clinical factors. Results: Relapse occurred in 28.9% (22/76) of the patients. The cumulative relapse rates were 10.5% at 1 year, 25.0% at 3 years, 34.9% at 5 years, and 43.0% at 10 years. In multivariate analysis, presence of sclerosing dacryoadenitis/sialadenitis at the time of initial diagnosis of AIP was an independent risk factor for relapse (HR 3.475, p = .009). The cumulative relapse rates of patients with sclerosing dacryoadenitis/sialadenitis reached 21.4% at 1 year, 56.0% at 3 years, and 78.0% at 5 years. Conclusions: Sclerosing dacryoadenitis/sialadenitis was a predictive factor for relapse in type 1 AIP during steroid therapy; in such cases, strict follow-up is necessary with relapse in mind.

4 February 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
YIYasutaka Ishii
Yasutaka Ishii
MSMasahiro Serikawa
Masahiro Serikawa
TTTomofumi Tsuboi
Tomofumi Tsuboi
RKRyota Kawamura
Ryota Kawamura
KTKen Tsushima
Ken Tsushima
KCKazuaki Chayama
Kazuaki Chayama
Pancreatic cancer has the poorest prognosis among all cancers, and early diagnosis is essential for improving the prognosis. Along with radiologic modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), endoscopic modalities play an important role in the diagnosis of pancreatic cancer. This review evaluates the roles of two of those modalities, endoscopic ultrasonography (EUS) and endoscopic retrograde cholangiopancreatography (ERCP), in the diagnosis of pancreatic cancer. EUS can detect pancreatic cancer with higher sensitivity and has excellent sensitivity for the diagnosis of small pancreatic cancer that cannot be detected by other imaging modalities. EUS may be useful for the surveillance of pancreatic cancer in high-risk individuals. Contrast-enhanced EUS and EUS elastography are also useful for differentiating solid pancreatic tumors. In addition, EUS-guided fine needle aspiration shows excellent sensitivity and specificity, even for small pancreatic cancer, and is an essential examination method for the definitive pathological diagnosis and treatment decision strategy. On the other hand, ERCP is invasive and performed less frequently for the purpose of diagnosing pancreatic cancer. However, ERCP is essential in cases that require evaluation of pancreatic duct stricture that may be early pancreatic cancer or those that require differentiation from focal autoimmune pancreatitis.